Alx Oncology Holdings annual stock-based compensation
2018
2019
2020
2021
2022
2023
2024
2025
Alx Oncology Holdings Stock-Based Compensation Growth & History (ALXO)
Alx Oncology Holdings's stock-based compensation was $12.6M for fiscal 2025.
View full Alx Oncology Holdings company overviewAlx Oncology Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $12.6M | −$14.5M | −53.57% |
| 2024 | 2024-12-31 | $27.1M | $820,000 | +3.12% |
| 2023 | 2023-12-31 | $26.3M | $2.4M | +10.21% |
| 2022 | 2022-12-31 | $23.8M | $9.9M | +71.33% |
| 2021 | 2021-12-31 | $13.9M | $8.5M | +155.96% |
| 2020 | 2020-12-31 | $5.4M | $5.1M | +1730.30% |
| 2019 | 2019-12-31 | $297,000 | $28,000 | +10.41% |
| 2018 | 2018-12-31 | $269,000 | — | — |
Alx Oncology Holdings quarterly stock-based compensation
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.7M | $547,000 | +25.61% |
| Q1 2026 | 2026-03-31 | $2.5M | −$2.7M | −51.90% |
| Q4 2025 | 2025-12-31 | $2.7M | −$3.2M | −53.81% |
| Q3 2025 | 2025-09-30 | $2.5M | −$4.4M | −63.74% |
| Q2 2025 | 2025-06-30 | $2.1M | −$5.1M | −70.55% |
| Q1 2025 | 2025-03-31 | $5.2M | −$1.8M | −25.81% |
| Q4 2024 | 2024-12-31 | $5.9M | −$863,000 | −12.84% |
| Q3 2024 | 2024-09-30 | $7.0M | −$12,000 | −0.17% |
| Q2 2024 | 2024-06-30 | $7.3M | $1.0M | +16.27% |
| Q1 2024 | 2024-03-31 | $7.0M | $680,000 | +10.71% |
| Q4 2023 | 2023-12-31 | $6.7M | $426,000 | +6.77% |
| Q3 2023 | 2023-09-30 | $7.0M | $757,000 | +12.20% |
| Q2 2023 | 2023-06-30 | $6.2M | $401,000 | +6.87% |
| Q1 2023 | 2023-03-31 | $6.4M | $850,000 | +15.45% |
| Q4 2022 | 2022-12-31 | $6.3M | $609,000 | +10.71% |
| Q3 2022 | 2022-09-30 | $6.2M | $2.0M | +48.10% |
| Q2 2022 | 2022-06-30 | $5.8M | $3.6M | +160.89% |
| Q1 2022 | 2022-03-31 | $5.5M | $3.7M | +205.61% |
| Q4 2021 | 2021-12-31 | $5.7M | $3.9M | +226.22% |
| Q3 2021 | 2021-09-30 | $4.2M | $3.5M | +508.27% |
| Q2 2021 | 2021-06-30 | $2.2M | −$616,000 | −21.59% |
| Q1 2021 | 2021-03-31 | $1.8M | $1.6M | +1092.05% |
| Q4 2020 | 2020-12-31 | $1.7M | — | — |
| Q3 2020 | 2020-09-30 | $689,000 | $603,000 | +701.16% |
| Q2 2020 | 2020-06-30 | $2.9M | $2.8M | +4655.00% |
| Q1 2020 | 2020-03-31 | $151,000 | — | — |
| Q3 2019 | 2019-09-30 | $86,000 | — | — |
| Q2 2019 | 2019-06-30 | $60,000 | — | — |
Alx Oncology Holdings stock-based compensation trends
Over the last five fiscal years, Alx Oncology Holdings's stock-based compensation increased from $5.4M to $12.6M, a change of $7.1M. The latest reported quarter, Q2 2026, shows $2.7M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alx Oncology Holdings source filings ↗